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Abstract   
 
Fluvoxamine (FVX) can be reduced at a  mer- 
cury-drop   electrode,   with   a   maximum   peak   current 
intensity being obtained at a potential of -0.7  V vs. Ag/ 
AgCl,  in  an  aqueous  electrolyte  solution  of  pH  2.  The 
compound was determined in a pharmaceutical product and 
in spiked human serum by square-wave adsorptive- 
stripping voltammetry (SWAdSV) after accumulation at 
the  electrode  surface,  under  batch  conditions.  Because 
the  presence  of  dissolved  oxygen  did  not  interfere  sig- 
niﬁcantly   with   the   analysis,   it   was   also   possible   to 
determine FVX in the pharmaceutical product by use of a  
ﬂow-injection  analysis  (FIA)  system  with  SWAdSV 
detection.  The  methods  developed  were  validated  and 
successfully  applied  to  the  quantiﬁcation  of  FVX  in  a 
pharmaceutical   product.   Recoveries   between   76   and 
89%   were   obtained    in   serum    analysis.    The   FIA– 
SWAdSV method enabled analysis of up to 120 samples 
per  hour  at  reduced  cost,  implying  the  possibility  of 
competing  with  the  chromatographic  methods  usually 
used  for  this  analysis. 
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Introduction 
 
Fluvoxamine (FVX, Fig. 1), a selective serotonin re- uptake 
inhibitor (SSRI), is primarily used as an antide- pressant 
drug but is also used to treat other psycholog- ical 
problems, for example obsessive–compulsive, panic, and 
post-traumatic stress disorders. 
For drug development and for treatment purposes  it is 
very important to be able to quantify the drug, and 
occasionally its metabolites, in a wide variety of samples 
(serum, plasma, urine, and pharmaceutical products) to 
establish its pharmacokinetics, metabolic pathway, dosage, 
etc. This implies the need for analytical methods with high 
sample-throughput, low limits of detection, and  low  
maintenance costs. 
After administration, FVX is extensively metabolised in 
the liver, without formation of active metabolites, and only 
negligible amounts are excreted unchanged in the urine. Its 
concentration in blood is diﬃcult to predict, because of 
high variability between individuals, and no therapeutic 
window has been established [1–3]. Thus, therapeutic drug 
monitoring might be helpful to im- prove  therapy  with  
FVX. 
Most FVX analysis is performed by  high-perfor- mance 
liquid chromatography (HPLC) coupled with spectrometric 
detectors, ultraviolet/diode array [4–17], mass spectrometric 
[18, 19] and ﬂuorimetric [20–22], for analysis of 
pharmaceuticals [8] and human serum or plasma [4–7, 10–
22]. This widespread usage of HPLC methods is justiﬁed by 
the high sensitivity and the low limit of detection usually 
obtained and the possibility of simultaneous analysis of the 
drug and its metabolites, which increases its use even 
further. The main disad- vantages of HPLC are the 
relatively long analysis times and high acquisition and 
maintenance costs. Several other methods, based on 
electrophoresis [23, 24], micellar electrokinetic capillary 
chromatography [25], isotachophoresis   [26],   gas   
chromatography    [27–30], 
ultraviolet–visible [31–36], infrared [31], and nuclear 
magnetic  resonance  [31,  37]  spectrometry,  have    also 
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Fig. 1  Chemical structure of  FVX 
 
 
been described, mainly for determination of FVX in 
pharmaceutical products. 
Electrochemical studies on the determination of FVX 
have also been reported [38–40]. All these studies fo- 
cussed on the determination of the antidepressant in 
pharmaceutical products using either square-wave or 
diﬀerential-pulse polarography under batch conditions. 
Adsorptive-stripping voltammetry (AdSV) is a tech- nique 
mainly used for the analysis of organic com- pounds, which 
can be accumulated at, for example, the hanging mercury 
drop electrode (HMDE) surface and afterwards stripped oﬀ 
by applying a potential scan [41]. The introduction of high-
scan-rate voltammetric tech- niques,  for  example  square-
wave  voltammetry  (SWV), 
increases the sensitivity of AdSV even further [42,    43]. 
In this study electroanalytical procedures for the 
determination of FVX in a pharmaceutical product and in 
spiked human serum under batch conditions are presented. 
Furthermore, an alternative method for determination of 
FVX in a pharmaceutical product has also been developed 
by adapting a square-wave-strip- ping  voltammetric 
method  for  use  in  a FIA system. 
 
 
 
Experimental 
 
Apparatus 
 
Voltammetric  measurements,  using  SWV  and  square- 
wave    adsorptive-stripping    voltammetry    (SWAdSV), 
were performed using a Autolab PGSTAT12 (Metrohm- 
EcoChemie)  potentiostat,  controlled  by  a  PC  by  use  of 
GPES  4.9  software  from  Metrohm-EcoChemie,  and  a 
Metrohm 663 VA stand containing a three-electrode cell 
(all  Metrohm).  This  voltammetric  cell  consisted  of  a 
multimode mercury working electrode, used in the static 
mercury-drop    position    (SMDE),    an    Ag/AgCl/KCl 
3  mol  L
-1     
reference   electrode,   and   a   glassy   carbon 
auxiliary  electrode.  This  system  was  used  both  under 
batch  conditions  and  as  the  detector  in  the  developed 
single  FIA  manifold. 
In the FIA system the solutions were transported to the 
voltammetric detection cell by means of a Gilson Minipuls  
3  peristaltic  pump,  using  PTFE  tubing      (i.d. 
0.8 mm). Samples and standards (Vinj=500 lL) were 
introduced into the carrier stream through a six-port 
Rheodyne type 5041 injection  valve. 
In the voltammetric ﬂow cell used [44] the glass 
capillary of the SMDE is inserted into a PTFE adapter head 
and the ﬂow is directed toward the mercury    drop. 
This adapter head enables reproducible repositioning of the 
glass capillary whenever the ﬂow cell is dismounted and 
then remounted. The adapter head, the reference electrode, 
and the counter-electrode are contained in a glass cell, 
which is ﬁlled with the solution used as the carrier 
stream. A drain ensures a constant level of solution is 
maintained during the   work. 
The   comparative   UV   spectrophotometric   method, 
using a Shimadzu UV-260 recording spectrophotometer, 
was  developed  internally  by  recording  the  absorption 
spectrum of a 5.0·10
-5  
mol  L
-1  
FVX  solution  between 
190  and  360  nm.  The  absorbance  peak  at  245  nm  was 
selected  for  quantiﬁcation  purposes. 
 
 
Reagents 
 
An   FVX   maleate   standard   was   provided   by   Solvay 
Pharmaceuticals    (Olst,    The    Netherlands)    and    used 
without  further  puriﬁcation.  Stock  solutions  of  FVX 
were   prepared   by   dissolution   of   precisely   weighed 
amounts of the standard in water. These stock solutions 
were  diluted  with  electrolyte  solution  to  furnish  the  de- 
sired  concentration.  All  other  reagents,  of  p.a.  quality, 
were  purchased   from   Merck  and  Sigma–Aldrich.   All 
solutions   were   prepared   using   deionised   water   (con- 
ductivity  <0.1  lS  cm
-1
). 
For optimisation of electrolyte pH,  several  buﬀers, for 
example phosphate, acetate, and ammonium, were used to 
cover a wide pH range (2–10). After optimisa- tion pH  2 
H3PO4/H2PO4    buﬀer (0.1  mol  L     ) was  used. 
 
Samples 
 
The pharmaceutical used for evaluation of the adequacy of 
the developed method was Dumyrox (Solvay Phar- 
maceuticals). This is currently the only commercially 
available FVX-containing pharmaceutical on the Por- 
tuguese market. The labelled value of FVX maleate per 
tablet is 50 mg. The tablets were weighed, ﬁnely pow- 
dered, and dissolved in 500.0 mL deionised water by 
sonication  for  10 min. 
For  batch  analysis  the  resulting  solution  was  diluted 
100-fold  with  electrolyte.  For  quantiﬁcation  purposes, 
using   the   standard   addition   method,   ﬁxed   volumes 
(117  lL)  of  the  diluted  sample  solution  were  placed  in 
ﬁve  20.00-mL  volumetric  ﬂasks  and  standard  additions 
between 0 and 1.20·10
-8  
mol  L
-1  
were made by adding 
increasing quantities of FVX standard. The volume was 
completed  with  electrolyte  and  the  contents  of  the  vol- 
umetric  ﬂasks  were  transferred  into  a  voltammetric  cell 
and  analysed. 
For  the  standard  addition  method  in  the  ﬂow-injec- 
tion  technique  six  standards  were  prepared  by  placing 
21.7-lL   samples   in   10.00-mL   volumetric   ﬂasks   and 
standard  additions  between  0  and  1.00·10
-6  
mol  L
-1 
were   made   by   adding   increasing   quantities   of   FVX 
standard.  The  volume  was  completed  with  electrolyte 
  
and the solutions were then injected directly  into  the FIA  
system. 
For  quantiﬁcation  by  the  comparative  UV  method 
ﬁve         standard         additions         between         0         and 
4.00·10
-5  
mol  L
-1     
were   made   to   1.000  mL   of   the 
sample   solution   contained   in   a   10.00-mL   volumetric 
ﬂask.  The  volume  was  completed  with  water  and  the 
solutions  were  ﬁltered  before  analysis. 
Serum  samples  were  obtained  from  healthy  individ- 
uals  who  were  not  receiving  treatment  with  FVX,  and 
analysed  on  the  same  day.  This  serum  (1.000  mL)  was 
spiked  with  an  amount  of  FVX  giving  a  concentration 
approximately      ﬁve      times      the      therapeutic      level 
(1.6·10
-6  
mol  L
-1
). After shaking, 1.5  mL NH4Cl/NH3 
buﬀer  solution,  pH  9.5,  was  added.  The  mixture  was 
shaken  mechanically  for  30  s  then  extracted  with  chlo- 
roform–2-isopropanol–n-heptane,   60:14:26   (v/v).  After 
shaking for 2  min and centrifuging for 10  min at 2800g, 
the  organic  layer  was  transferred  to  another  receptacle and  
evaporated  under  a  stream  of  nitrogen  [10].  The dried 
extract was dissolved in 5.000  mL electrolyte and a 923-lL 
portion was added to 20.00  mL electrolyte in the 
voltammetric    cell    to    furnish    a    concentration    of 
1.5·10
-8  
mol  L
-1
. Again, the standard addition method 
was     used,     and     the     additions,     between     0     and 
3.02·10
-8  
mol  L
-1
,  were  made  directly  in  the  voltam- 
metric  cell. 
 
 
Validation  procedure 
 
When the optimum experimental conditions had been found, 
validation of the methods was  performed.  For this purpose, 
the linear range, limit of detection (LOD), limit of 
quantiﬁcation (LOQ), repeatability,  intermedi- ate 
precision, recovery, and selectivity were evaluated [45]. 
The  linear  range  was  determined  by  analysing  FVX 
solutions in the ranges 1.00·10
-9  
to 1.00·10
-6  
mol  L
-1 
and  1.00·10
-7   
to  5.00·10
-5  
mol  L
-1   
for  the  
SWAdSV and   FIA–SWAdSV   methods,   respectively.   
The   LOD and  LOQ  were  calculated  from  the  linear  
calibration plot  [46]. 
Repeatability   and   intermediate   precision   were   as- 
sessed  at  three  concentrations.  For  the  SWAdSV  meth- 
od   concentration   levels   of   3.0·10
-8
,   1.0·10
-7
,   and 
1.7·10
-7  
mol  L
-1    
(tacc    30  s)   and   1.0·10
-8
,   4.0·10
-
8
, and  8.0·10
-8  
mol  L
-1   
(tacc   60  s)  were  used.  The  
preci- sion  of  the  ﬂow-injection  method  was  evaluated  by  
use of   2.0·10
-6
,   5.0·10
-6
,   and   8.0·10
-6  
mol  L
-1     
FVX 
solutions. To assess the repeatability ﬁve replicate 
measurements of each solution were made in a short period 
of time. To determine intermediate precision the solutions 
were each analysed ﬁve times per day for three consecutive 
days. 
The  accuracy  of  the  procedure  was  veriﬁed  by  per- 
forming   recovery   assays   at   three   concentrations,   in 
triplicate. In the evaluation of the SWAdSV method two 
preconcentration times were used (tacc  30 and 60  s), and a      
solution      of      the      pharmaceutical      containing 
2.0·10
-8  
mol  L
-1  
FVX  was  spiked  with  FVX  
standard to  furnish  ﬁnal  concentrations  of  4.0·10-8,  
6.0·10
-8
, and  8.0·10
-8  
mol  L
-1    
(i.e.  additions  of  2.0,  
4.0,  and 6.0·10
-8  
mol  L
-1
).    For    the    ﬂow-injection    
method spikes   of   1.5·10
-6
,   3.0·10
-6
,   and   4.5·10
-6  
mol  L
-1 
were  added  to  a  solution  of  the  pharmaceutical  
with  a FVX concentration of 3.5·10
-6  
mol  L
-1
, to 
obtain ﬁnal concentrations        of        5.0·10-6,        
6.5·10
-6
,        and 8.0·10
-6  
mol  L
-1  
FVX. 
 
 
Results 
 
Analysis  of  ﬂuvoxamine  using   SWAdSV 
 
The   electrochemical   behaviour   of   FVX   was   studied 
under  batch  conditions  by  SWV  and  SWAdSV  and  it 
was veriﬁed that the analytical signal obtained decreased 
with  increasing  electrolyte  pH.  A  maximum  peak  cur- 
rent  intensity  (ip),  with  a  good  repeatability,  was  ob- 
tained  at  pH  2.  At  this  pH  FVX  gave  a  reduction  peak 
at     approximately     -0.7  V,     which     increased     with 
increasing   accumulation   time   (tacc)   (Fig.  2,I).   For   a 
1·10
-8  
mol  L
-1  
FVX solution this increase is signiﬁcant 
for  up  to  approximately  2  min  (Fig.  2,II)  at  an  opti- 
mised   accumulation   potential   (Eacc)   of   -0.5  V,   after 
 
 
Fig. 2  I Square  wave 
voltammograms  obtained  from 
5·10
-8  
mol  L
-1  
FVX  
solution. Eacc=-0.5  V;  f=100  
Hz; 
DEs=3  mV;  DEp=30 mV; 
tacc=(1) 0, (2) 60, and (3) 120 s. 
II Eﬀect  of tacc  on ip   for 
1·10
-8  
mol  L
-1  
FVX  solution 
 which  the  increase  of  ip   levels  oﬀ,  possibly  because of 
 
 Table  2  Results  from  serum  analysis (SWAdSV)   
saturation   coverage   of   the   drop   and/or competitive 
adsorption. 
Several experimental conditions related to the square- 
Sample [FVX]found 
(lmol  L
-1
) 
[FVX]added 
(lmol  L
-1
) 
Recovery (%) 
wave potential scan, for example frequency (f),  pulse step 
(DEs), and pulse amplitude (DEp), were studied and 
optimised to obtain maximum ip  and  repeatability. These 
conditions are interrelated and have a combined eﬀect on the 
analytical signal. Diﬀerent values for f (10– 200 Hz), DEs 
(1–8 mV), and DEp (10–50 mV) were used, and  led  to  the  
optimum  conditions:   f=200 Hz, DEs=6 mV, and DEp=30 
mV, in agreement with results obtained by Nevado et al. 
[40]. Although an optimum frequency of 200 Hz was 
established, several other fre- quencies were used 
throughout this work to obtain ei- ther better peak deﬁnition 
or  linearity. 
Variation  of  ip   with  drug  concentration  (CFVX),  un- 
der  the  optimised  conditions  with  a  tacc    of  30  s,  was 
represented         by         the         straight-line         equation 
ip=(1.33±0.01)CFVX+(4.87±0.87)·10
-9 
(r=0.999; 
n=14)      within      the      linear      range      6.00·10
-9         
to 
2.80·10
-7  
mol  L
-1    
FVX.   The   LOD   and   LOQ   
were calculated   and   found   to   be   4.7·10
-9  
mol  L
-1     
and 1.6·10
-8  
mol  L
-1
,     respectively.     The     results     
from assessment  of  the  precision,  expressed  as  the  
relative standard  deviation  (RSD),  are  listed  in  Table  1;  
they imply  the  method  is  precise.  Furthermore,  the  
recovery values shown in Table  1 indicate the method is 
accurate and  selective  for  FVX  determination. 
In  the  application  of  the  SWAdSV  method  to  the 
quantiﬁcation  of  FVX  in  Dumyrox,  analyses  were  per- 
formed using a standard addition interval between 0 and 
1.20·10
-8  
mol  L
-1    
and  a  tacc    of  30  s.  The  result  ob- 
tained, 50.3±1.3  mg FVX maleate/tablet (n=3), was in 
good  agreement  with  the  labelled  value  (50  mg  FVX 
maleate/tablet)   and   with   the   result   provided   by   the 
comparative  UV  method,  51.6±1.0  mg  FVX  maleate/ 
tablet  (n=3). 
Table 2 shows the results obtained  from application of 
the method to quantify FVX in six spiked serum samples, 
using standard additions and f of 50 Hz. The recovery was 
calculated to assess the accuracy of the method. Figure 3 
shows the voltammograms obtained from  a  typical  FVX  
analysis  in  human serum. 
 
Table 1 Results from evaluation of the precision and accuracy of 
SWAdSV 
Property tacc   30 s tacc   60 s 
Repeatability   (RSD  %) 1.7 (30) 0.6 (10) 
0.9 (100) 1.3 (40) 
0.8 (170) 0.5 (80) 
Intermediate precision (RSD %)     1.9   (30) 2.1 (10) 
1.6 (100) 1.7 (40) 
1.2 (170) 0.7 (80) 
Recovery (%) 98.6±1.8  (20)      98.2±2.2 (20) 
99.2±1.3  (40) 99.6±1.4  (40) 
99.5±0.9  (60) 98.6±0.5  (60) 
 
 
Concentrations,  in  nmol   L
-1
,  are  given  in  parentheses 
1 1.23 1.57 78.3 
2 1.19 75.8 
3 1.33 84.7 
4 1.39 88.5 
5 1.31 83.4 
6 1.24 79.0 
 
 
 
 
The  possibility  of  avoiding  time-consuming  deoxy- 
genation  of  the  analysed  solution  was  also  studied.  It 
was  observed  that  dissolved  oxygen  did  not  interfere 
signiﬁcantly   when   tacc    was   30  s   (Eacc=-0.5  V),   even 
when     low     frequencies     and     concentrations     (10
-8 
mol  L
-1
)  were  used  (Fig.  4). 
The possibility of performing the measurements without 
the previous deoxygenation step enables signif- icant 
reduction of the analysis time and the possibility of 
including the HMDE in an FIA system, without prior or 
on-line oxygen removal, which leads to an increase in 
sample throughput. 
 
 
Analysis of ﬂuvoxamine using   FIA–SWAdSV 
 
On the basis of the previous results  a  single-manifold FIA 
system was developed in which the adsorption step at the 
HMDE was performed while the sample solution slug was 
ﬂowing through the adapter  head containing the  mercury  
electrode  [44].  The  square  wave  voltam- 
 
 
 
 
Fig. 3  Typical  voltammograms  obtained  from  FVX  in  a  contam- 
inated   human   serum   sample   after   liquid–liquid   extraction   and 
using  the  standard  addition  method.  Standard  additions  of  FVX 
(10
-8  
mol  L
-1
):  (1)  0;  (2)  1.01;  (3)  2.02;  (4)  3.02.  Eacc=-0.5  V; 
t    =30 s;  f=50  Hz;  DE =6 mV;  DE  =30  mV 
acc s p 
  
Fig. 4  Eﬀect  of  dissolved oxygen  
on  the  voltammetric determination  
of  FVX.  FVX concentration: 
(1) 0; (2) 5·10
-8
; (3)  5·10
-7  
mol  
L
-1
. 
Deoxygenation time: I 600  and 
II 0  s. Eacc=-0.5  V; tacc=30  s; 
f=50 Hz; DEs=6 mV; 
DEp=30 mV 
 
 
 
 
 
 
 
metric scan was also performed under ﬂow conditions 
and no perturbation of the voltammetric signal because of 
the ﬂow of electrolyte was observed. The length of the tube 
between the injection valve and the HMDE  was kept as 
short as possible to minimise dispersion of the injected 
sample, and to keep the injected slug as intact as possible. 
It    was    shown    that    ﬂow    rates    up    to      about 
1.4 mL  min-1   had  no  signiﬁcant  eﬀect  on  ip   but  that 
repeatability decreased slightly with increasing ﬂow rate. A  
ﬂow  rate  of  1.1  mL  min-1  was  regarded  as  adequate for 
analysis of FVX, being a good compromise between 
sample  throughput  and  repeatability.  Using  this  ﬂow 
rate, an injection volume of 500  lL and a tube length of 
50  cm between  the  injector  and the  detector, a  constant 
concentration    proﬁle    between    ±20    and    35  s    after 
injection  was  obtained  (Fig.  5).  The  length  of  this  zone 
depends on the injection volume and the ﬂow rate, which 
can  easily  be  controlled.  The  adsorption  step  and  the 
voltammetric scan should be performed within this time 
interval. 
By performing accumulation and measurement in the 
established  interval,  several  experimental  conditions  of the  
voltammetric  detection  system  were  gradually  opti- mised  
to  obtain  maximum  sensitivity,  repeatability  and high  
sample  throughput.  The  optimum  Eacc   was  found to  be  
-0.6  V,  at  which  an  increase  of  tacc  from  0  to  5  s led to 
a marked increase of ip. For longer tacc  (up to 10  s) ip   levels  
oﬀ,  possibly  because  of  saturation  coverage  of 
 
the drop, competitive adsorption, or removal of species by 
the ﬂow. A tacc of 5 s was regarded as suitable for use. Up to 
120 samples per hour could be analysed using the proposed 
ﬂow system. 
Several frequencies (50–400 Hz), DEs (1–11 mV), and 
DEp (10–60 mV) were studied. The optimum conditions 
for  determination  of  FVX  were  established   as f=250  
Hz,  DEs=7  mV,  and  DEp=30    mV. 
Variation  of  ip  with  CFVX,  under  the  optimised  con- 
ditions,  was  represented  by  the  straight-line  equation 
ip=(0.378±0.005)CFVX–(2.54±2.83)·10
-8         
(r=0.999; 
n=8)      within      the      linear      range      5.00·10
-7         
to 
1.00·10
-5  
mol  L
-1    
FVX.   The   LOD   and   LOQ   
were found   to   be   4.4·10
-7    
and   1.5·10
-6  
mol  L
-1
,   
respec- tively. Results from evaluation of precision, 
expressed as the  relative  standard  deviation  (RSD),  are  
listed  in  Ta- ble  3;   they   imply   the   method   is   precise.   
From   the recovery  values  shown  in  Table  3  it  can  be  
concluded that   the   method   is   accurate   and   selective   
for   FVX determination. 
To evaluate the adequacy of the method it was ap- 
plied to the quantiﬁcation of FVX in Dumyrox. Typical 
ﬂow-injection voltammograms obtained during quanti- 
ﬁcation of FVX in Dumyrox are shown in Fig. 6. The 
result, 55.0±2.2 mg FVX maleate/tablet (n=3), is in good 
agreement with the labelled value (50 mg FVX 
maleate/tablet) and with the result obtained from a UV 
method used for comparison, 54.4±4.1 mg FVX male- 
ate/tablet (n=3). 
 
 
 
 
 
Fig. 5  Variation    of    ip      with    time    after    sample    injection    for 
1.0·10
-6  
mol  L
-1  
FVX  solution.  tacc=5  s 
 
 
Table 3 Results from evaluation of the precision and accuracy of 
FIA–SWAdSV 
 
 
Property 
 
 
Repeatability   (RSD  %) 1.2 (2.0) 
1.1 (5.0) 
1.6 (8.0) 
Intermediate Precision (RSD %) 2.4 (2.0) 
2.1 (5.0) 
1.6 (8.0) 
Recovery (%) 101.2±4.9  (1.5) 
99.3±4.0 (3.0) 
100.2±0.9 (4.5) 
 
 
Concentrations,  in  lmol  L
-1
,  are  given  in  parentheses 
  
 
 
 
Fig. 6  Typical ﬂow-injection voltammograms obtained for FVX in 
Dumyrox using the standard addition method. Standard additions of  
FVX  (10-7  mol  L-1):  (1)  0;  (2) 2.00;  (3)  4.00; (4) 6.00;  (5)  8.00; (6)    
10.0.    Eacc=-0.6  V;    tacc=5  s;    f=250  Hz;    DEs=7.05 mV; 
DEp=30  mV;  ﬂow  rate=1.1  mL  min
-1
 
 
 
 
Conclusions 
 
On the basis of the electrochemical behaviour of FVX, 
SWAdSV and FIA–SWAdSV analytical  methods  have 
been developed for quantiﬁcation of the drug in a 
pharmaceutical product and in spiked human serum. Both 
methods can be applied as good alternatives to the 
chromatographic methods used for  determination of FVX 
in pharmaceutical preparations. For quantiﬁcation of FVX 
in serum further optimisation is needed to compete with the 
techniques most widely used for this analysis. Both methods 
have the advantages of high sample throughput and 
signiﬁcantly reducing analysis time  and cost. 
Further investigation is being undertaken to deter- 
mine FVX in biological samples using on-line sample 
extraction and the HMDE ﬂow cell as an HPLC detector. 
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